Toxic encephalopathy

Seminars in Neurology

Volumn 31, Issue 2, 2011, Pages 184-193

  Dobbs, Michael R ^a,b,c  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY COLLEGE OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

encephalopathy; neurotoxicology; neurotoxin; Toxic encephalopathy

Indexed keywords

4 METHYLPYRAZOLE; ALCOHOL; ALUMINUM; ATROPINE; CARBON DISULFIDE; CARBON MONOXIDE; CYCLOSPORIN; DIAZEPAM; DIMERCAPROL; EDETIC ACID; ETHYLENE GLYCOL; HEAVY METAL; HYDROGEN SULFIDE; IMMUNOSUPPRESSIVE AGENT; INTERFERON; LEAD; MANGANESE; METHYLMERCURY; NEUROTOXIN; OBIDOXIME; ORGANOMERCURY COMPOUND; PENICILLAMINE; PESTICIDE; PRALIDOXIME; SUCCIMER; THALLIUM; TOLUENE; TRICHLOROETHYLENE; UNINDEXED DRUG; VINCRISTINE;

ARSENIC POISONING; ARTICLE; BRAIN DISEASE; BRAIN INJURY; BRAIN TOXICITY; CARBON MONOXIDE INTOXICATION; CHELATION THERAPY; CLINICAL EXAMINATION; COMMON COMPLEX ENCEPHALOPATHY; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DRUG MECHANISM; ELECTROENCEPHALOGRAPHY; ELECTROMYOGRAPHY; ENVIRONMENTAL EXPOSURE; GRAY MATTER; HEART ARRHYTHMIA; HUMAN; IMMUNOASSAY; IMMUNOSUPPRESSIVE TREATMENT; INJURY SEVERITY; INTOXICATION; KIDNEY TUBULE NECROSIS; LABORATORY TEST; LEAD POISONING; LEUKOENCEPHALOPATHY; MEDICAL HISTORY; MERCURIALISM; MIXED TOXIC ENCEPHALOPATHY; NEUROIMAGING; NEUROMANGANISM; NEUROPHYSIOLOGY; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OXYGEN THERAPY; PESTICIDE POISONING; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; RESUSCITATION; SEIZURE; TOXIC CORTICAL ENCEPHALOPATHY; TOXIC LEUKOENCEPHALOPATHY; WHITE MATTER;

ANIMALS; ENVIRONMENTAL EXPOSURE; HAZARDOUS SUBSTANCES; HUMANS; NEUROTOXICITY SYNDROMES; NEUROTOXINS; PESTICIDES;

EID: 79956215976     PISSN: 02718235     EISSN: 10989021     Source Type: Journal    
DOI: 10.1055/s-0031-1277989     Document Type: Article

References (83)

1. Hunter D. The Diseases of Occupations. 6th ed. London Hodderand Stoughton 1978 251
2. Anger W K. Workplace exposures. In: Annau Z ed. Neurobehavioral Toxicology. Baltimore, MD Johns Hopkins 1986
3. National Institute for Occupational Safety and Health. National Occupational Hazard Survey, 1972-74. DHEW Publication No. (NIOSH) 78-114. Cincinnati, OH National Institute for Occupational Health and Safety 1977
4. Spencer P S., Schaumburg H H. Experimental and Clinical Neurotoxicology. New York Oxford University Press 2000
5. Dobbs M R. Clinical Neurotoxicology: Syndromes, Substances, Environments. Philadelphia Saunders 2009
6. Grandjean P, Landrigan P J. Developmental neurotoxicity of industrial chemicals. Lancet 2006 368 9553 2167-2178 (Pubitemid 44894541)
7. Feldman R G. Approach to Diagnosis: Occupational and Environmental Neurotoxicology. Philadelphia Lippincott-Raven 1999
8. Bull S. Review of Environmental Chemicals and Neurotoxicity: Focus on Neurological Diseases. Didcot Centre for Radiation, Chemical and Environmental Hazards 2007
9. Zuccoli G, Siddiqui N, Cravo I, Bailey A, Gallucci M, Harper C G. Neuroimaging findings in alcohol-related encephalopathies. AJR Am J Roentgenol 2010 195 6 1378-1384
10. Brust J C. Ethanol and cognition: indirect effects, neurotoxicity and neuroprotection: a review. Int J environ Res Public Health 2010 7 4 1540-1557
11. Brust J C. Acute neurologic complications of drug and alcohol abuse. J Acquir Immune Defic Syndr 2002 31 Suppl 2 S29-S34 (Pubitemid 35190556)
12. Dobbs M R. Clinical Neurotoxicology: Syndromes, Substances, Environments. Philadelphia Saunders 2009 chapters 30-34
13. Chang K H., Han M H., Kim H S., Wie B A., Han M C. Delayed encephalopathy after acute carbon monoxide intoxication: MR imaging features and distribution of cerebral white matter lesions. Radiology 1992 184 1 117-122
14. Merimsky O, Loewenstein A, Chaitchik S. Cortical blindnessa catastrophic side effect of vincristine. Anticancer Drugs 1992 3 4 371-373
15. Merimsky O, Nisipeanu P, Loewenstein A, Reider-Groswasser I, Chaitchik S. Interferon-related cortical blindness. Cancer Chemother Pharmacol 1992 29 4 329-330
16. Young D C., Mitchell A, Kessler J, Christman J E. Cortical blindness and seizures possibly related to cisplatin, vinblastine, and bleomycin treatment of ovarian dysgerminoma. J Am Osteopath Assoc 1993 93 4 502-504, 507
17. Filley C M. Toxic leukoencephalopathy. Clin Neuropharmacol 1999 22 5 249-260 (Pubitemid 29506393)
18. Moawad F J., Hartzell J D., Biega T J., Lettieri C J. Transient blindness due to posterior reversible encephalopathy syndrome following ephedra overdose. South Med J 2006 99 5 511-514 (Pubitemid 43804521)
19. Fugate J E., Claassen D O., Cloft H J., Kallmes D F., Kozak O S., Rabinstein A A. Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. Mayo Clin Proc 2010 85 5 427-432
20. Mueller-Mang C, Mang T, Pirker A, Klein K, Prchla C, Prayer D. Posterior reversible encephalopathy syndrome: do predisposing risk factors make a difference in MRI appearance? Neuroradiology 2009 51 6 373-383
21. Cooney M J., Bradley W G., Symko S C., Patel S T., Groncy P K. Hypertensive encephalopathy: complication in children treated for myeloproliferative disordersreport of three cases. Radiology 2000 214 3 711-716 (Pubitemid 30115369)
22. Morris E B., Laningham F H., Sandlund J T., Khan R B. Posterior reversible encephalopathy syndrome in children with cancer. Pediatr Blood Cancer 2007 48 2 152-159 (Pubitemid 44958271)
23. Sonchez-Carpintero R, Narbona J, Lopez de Mesa R, Arbizu J, Sierrasesomaga L. Transient posterior encephalopathy induced by chemotherapy in children. Pediatr Neurol 2001 24 2 145-148 (Pubitemid 32280299)
24. Pihko H, Tyni T, Virkola K et al. Transient ischemic cerebral lesions during induction chemotherapy for acute lymphoblastic leukemia. J Pediatr 1993 123 5 718-724 (Pubitemid 23316422)
25. Dzudie A, Boissonnat P, Roussoulieres A et al. Cyclosporine-related posterior reversible encephalopathy syndrome after heart transplantation: should we withdraw or reduce cyclosporine?: case reports. Transplant Proc 2009 41 2 716-720
26. Saeed B, Abou-Zor N, Amer Z, Kanani I, Hilal M. Cyclosporin-A induced posterior reversible encephalopathy syndrome. Saudi J Kidney Dis Transpl 2008 19 3 439-442
27. Cosottini M, Lazzarotti G, Ceravolo R, Michelassi M C., Canapicchi R, Murri L. Cyclosporine-related posterior reversible encephalopathy syndrome (PRES) in non-transplant patient: a case report and literature review. Eur J Neurol 2003 10 4 461-462
28. Vahidnia A, van der Voet G B., de Wolff F A. Arsenic neurotoxicitya review. Hum Exp Toxicol 2007 26 10 823-832
29. Szlatenyi C S., Wang R Y. Encephalopathy and cranial nerve palsies caused by intentional trichloroethylene inhalation. Am J Emerg Med 1996 14 5 464-466
30. McCunney R J. Diverse manifestations of trichloroethylene. Br J Ind Med 1988 45 2 122-126 (Pubitemid 18065642)
31. Greenberg S A. Acute demyelinating polyneuropathy with arsenic ingestion. Muscle Nerve 1996 19 12 1611-1613 (Pubitemid 26412120)
32. London Z, Albers J W. Toxic neuropathies associated with pharmaceutic and industrial agents. Neurol Clin 2007 25 1 257-276 (Pubitemid 46283307)
33. Bartynski W S. Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features. AJNR Am J Neuroradiol 2008 29 6 1036-1042 (Pubitemid 351954863)
34. Bartynski W S., Boardman J F. Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol 2007 28 7 1320-1327 (Pubitemid 47309666)
35. Oliver L. Laboratory assessment of exposure to neurotoxic agents. In: Dobbs M R. ed. Clinical Neurotoxicology: Syndromes, Substances, Environments. Philadelphia Saunders 2009 213-221
36. Schwartz B S., Lee B K., Lee G S. et al. Associations of blood lead, dimercaptosuccinic acid-chelatable lead, and tibia lead with neurobehavioral test scores in South Korean lead workers. Am J Epidemiol 2001 153 5 453-464 (Pubitemid 32185082)
37. Campara P, D'Andrea F, Micciolo R, Savonitto C, Tansella M, Zimmermann-Tansella C. Psychological performance of workers with blood-lead concentration below the current threshold limit value. Int Arch Occup Environ Health 1984 53 3 233-246 (Pubitemid 14222309)
38. Stokes L, Letz R, Gerr F et al. Neurotoxicity in young adults 20 years after childhood exposure to lead: the Bunker Hill experience. Occup Environ Med 1998 55 8 507-516 (Pubitemid 28393907)
39. Landrigan P J., Todd A C. Lead poisoning. West J Med 1994 161 2 153-159 (Pubitemid 24256861)
40. Saryan L A., Zenz C. Lead and its compounds. In: Saryan L A. Zenz C eds. Occupational Medicine. 3rd ed. St. Louis, MO Mosby 1994 506-541
41. Karri S K., Saper R B., Kales S N. Lead encephalopathy due to traditional medicines. Curr Drug Saf 2008 3 1 54-59 (Pubitemid 351223154)
42. Canfield R L., Henderson C R. Jr, Cory-Slechta D A., Cox C, Jusko T A., Lanphear B P. Intellectual impairment in children with blood lead concentrations below 10 microg per deciliter. N Engl J Med 2003 348 16 1517-1526 (Pubitemid 36437928)
43. Perelman S, Hertz-Pannier L, Hassan M, Bourrillon A. Lead encephalopathy mimicking a cerebellar tumor. Acta Paediatr 1993 82 4 423-425 (Pubitemid 23142863)
44. Tozon M, Tozon D, Salan A, Hekimolu B. Lead encephalopathy: CT and MR findings. J Comput Assist Tomogr 2002 26 3 479-481 (Pubitemid 34564233)
45. Reyes P F., Gonzalez C F., Zalewska M K., Besarab A. Intracranial calcification in adults with chronic lead exposure. AJR Am J Roentgenol 1986 146 2 267-270 (Pubitemid 16143915)
46. American Academy of Pediatrics Committee on Environmental Health. Lead exposure in children: prevention, detection, and management. Pediatrics 2005 116 4 1036-1046
47. Freeman J W., Couch J R. Prolonged encephalopathy with arsenic poisoning. Neurology 1978 28 8 853-855 (Pubitemid 8382995)
48. Bolla-Wilson K, Bleecker M L. Neuropsychological impairment following inorganic arsenic exposure. J Occup Med 1987 29 6 500-503 (Pubitemid 17108206)
49. Ratnaike R N. Acute and chronic arsenic toxicity. Postgrad Med J 2003 79 933 391-396 (Pubitemid 36993968)
50. Vahidnia A, van der Voet G B., de Wolff F A. Arsenic neurotoxicitya review. Hum Exp Toxicol 2007 26 10 823-832
51. London Z, Albers J W. Toxic neuropathies associated with pharmaceutic and industrial agents. Neurol Clin 2007 25 1 257-276 (Pubitemid 46283307)
52. Matschullat J. Arsenic in the geospherea review. Sci Total Environ 2000 249 1-3 297-312
53. Mukherjee S C., Rahman M M., Chowdhury U K. et al. Neuropathy in arsenic toxicity from groundwater arsenic contamination in West Bengal, India. J Environ Sci Health A Tox Hazard Subst Environ Eng 2003 38 165-183 (Pubitemid 36267801)
54. Lund A. Distribution of thallium in the organism and its elimination. Acta Pharmacol Toxicol (Copenh) 1956 12 3 251-259
55. Tromme I, Van Neste D, Dobbelaere F et al. Skin signs in the diagnosis of thallium poisoning. Br J Dermatol 1998 138 2 321-325 (Pubitemid 28114140)
56. Moeschlin S. Thallium poisoning. Clin Toxicol 1980 17 1 133-146 (Pubitemid 10005916)
57. Mulkey J P., Oehme F W. A review of thallium toxicity. Vet Hum Toxicol 1993 35 5 445-453 (Pubitemid 23294232)
58. Rusyniak D E., Kao L W., Nanagas K A. et al. Dimercaptosuccinic acid and Prussian Blue in the treatment of acute thallium poisoning in rats. J Toxicol Clin Toxicol 2003 41 2 137-142 (Pubitemid 36520463)
59. Chalela J A., Bonillha L, Neyens R, Hays A. Manganese encephalopathy: an under-recognized condition in the intensive care unit. Neurocrit Care 2010; December 21 (Epub ahead of print)
60. Hauser R A., Zesiewicz T A., Martinez C, Rosemurgy A S., Olanow C W. Blood manganese correlates with brain magnetic resonance imaging changes in patients with liver disease. Can J Neurol Sci 1996 23 2 95-98 (Pubitemid 26186474)
61. Butterworth R F., Spahr L, Fontaine S, Layrargues G P. Manganese toxicity, dopaminergic dysfunction and hepatic encephalopathy. Metab Brain Dis 1995 10 4 259-267 (Pubitemid 26042535)
62. Sata F, Araki S, Murata K, Aono H. Behavior of heavy metals in human urine and blood following calcium disodium ethylenediamine tetraacetate injection: observations in metal workers. J Toxicol Environ Health A 1998 54 3 167-178 (Pubitemid 28427013)
63. Herrero Hernandez E, Discalzi G, Valentini C et al. Follow-up of patients affected by manganese-induced Parkinsonism after treatment with CaNa2EDTA. Neurotoxicology 2006 27 3 333-339
64. Siegler R W., Nierenberg D W., Hickey W F. Fatal poisoning from liquid dimethylmercury: a neuropathologic study. Hum Pathol 1999 30 6 720-723 (Pubitemid 29266735)
65. Lee B K., Lee S H., Lee K M. et al. Dose-dependent increase in subjective symptom prevalence among toluene-exposed workers. Ind Health 1988 26 1 11-23
66. Lazar R B., Ho S U., Melen O, Daghestani A N. Multifocal central nervous system damage caused by toluene abuse. Neurology 1983 33 10 1337-1340 (Pubitemid 13021198)
67. Yocel M, Takagi M, Walterfang M, Lubman D I. Toluene misuse and long-term harms: a systematic review of the neuropsychological and neuroimaging literature. Neurosci Biobehav Rev 2008 32 5 910-926
68. Bernad P G., Newell S, Spyker D A. Neurotoxicity and behavior abnormalities in a cohort chronically exposed to trichloroethylene. Vet Hum Toxicol 1987 29 475
69. Perbellini L, Olivato D, Zedde A, Miglioranzi R. Acute trichloroethylene poisoning by ingestion: clinical and pharmacokinetic aspects. Intensive Care Med 1991 17 4 234-235
70. Feldman R G., White R F., Currie J N., Travers P H., Lessell S. Long-term follow-up after single toxic exposure to trichloroethylene. Am J Ind Med 1985 8 2 119-126 (Pubitemid 15228712)
71. Lawrence W H., Partyka E K. Chronic dysphagia and trigeminal anesthesia after trichloroethylene exposure. Ann Intern Med 1981 95 6 710 (Pubitemid 12173178)
72. Leandri M, Schizzi R, Scielzo C, Favale E. Electrophysiological evidence of trigeminal root damage after trichloroethylene exposure. Muscle Nerve 1995 18 4 467-468
73. Szlatenyi C S., Wang R Y. Encephalopathy and cranial nerve palsies caused by intentional trichloroethylene inhalation. Am J Emerg Med 1996 14 5 464-466
74. Gash D M., Rutland K, Hudson N L. et al. Trichloroethylene: Parkinsonism and complex 1 mitochondrial neurotoxicity. Ann Neurol 2008 63 2 184-192 (Pubitemid 351355297)
75. Occupational Safety and Health Administration. Occupational Safety and Health Guideline for Carbon Monoxide. Washington, DC Department of Labor Available at: http://www.osha.gov/SLTC/healthguidelines/carbonmonoxide/ recognition.html Accessed January 2011
76. Choi I S. Delayed neurologic sequelae in carbon monoxide intoxication. Arch Neurol 1983 40 7 433-435
77. Min S K. A brain syndrome associated with delayed neuropsychiatric sequelae following acute carbon monoxide intoxication. Acta Psychiatr Scand 1986 73 1 80-86 (Pubitemid 16123888)
78. Rusyniak D E. Pearls and pitfalls in the approach to patients with neurotoxic syndromes. Semin Neurol 2001 21 4 407-416 (Pubitemid 34027544)
79. Hardy K R., Thom S R. Pathophysiology and treatment of carbon monoxide poisoning. J Toxicol Clin Toxicol 1994 32 6 613-629 (Pubitemid 24372548)
80. Gorman D, Drewry A, Huang Y L., Sames C. The clinical toxicology of carbon monoxide. Toxicology 2003 187 1 25-38 (Pubitemid 36385053)
81. Blumenthal I. Carbon monoxide poisoning. J R Soc Med 2001 94 6 270-272 (Pubitemid 32588181)
82. Tapeantong T, Poungvarin N. Delayed encephalopathy and cognitive sequelae after acute carbon monoxide poisoning: report of a case and review of the literature. J Med Assoc Thai 2009 92 10 1374-1379
83. National Research Council of The National Academies. Toxicity Testing in the 21st Century: A Vision and a Strategy. Washington, DC The National Academies Press 2007